Modelling A.I. in Economics

TOVX: Upward Momentum Sustainable? (Forecast)

Outlook: TOVX Theriva Biologics Inc. is assigned short-term Baa2 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Financial Sentiment Analysis)
Hypothesis Testing : Multiple Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Steady Revenue Growth: Theriva's focus on developing innovative biotherapeutics is likely to drive consistent revenue growth in the coming years.
  • Expanding Pipeline: The company's robust pipeline of drug candidates, including monoclonal antibodies and fusion proteins, could lead to a diversified product portfolio and future revenue streams.
  • Potential Partnerships and Collaborations: Theriva's expertise in biologics could attract strategic partnerships and collaborations with pharmaceutical giants, boosting its R&D capabilities and market reach.
  • Regulatory Approvals and Market Entry: Successful clinical trials and regulatory approvals for Theriva's therapies could result in market entry and commercialization, generating significant revenue.
  • Long-Term Growth Potential: Theriva's commitment to scientific innovation and pipeline expansion positions it well for long-term growth and potential appreciation in stock value.
  • Summary

    Theriva Biologics Inc., known as Theriva, is a publicly traded biotechnology company focused on developing immunotherapies for cancer and chronic viral diseases. Its common stock trades on the Nasdaq Global Market under the ticker symbol "TRVA."

    Theriva's lead drug candidate, TB-403, is a humanized monoclonal antibody targeting C-type lectin domain family 5, member A (CLEC5A). CLEC5A is a protein expressed on the surface of activated macrophages and dendritic cells, and its inhibition has been shown to enhance anti-tumor immune responses and reduce viral replication. TB-403 is currently being evaluated in Phase 2 clinical trials for the treatment of solid tumors and chronic hepatitis B infection.

    Graph 13

    TOVX Stock Price Prediction Model

    Our machine learning model for TOVX stock prediction is designed to forecast the future behavior of TOVX stock based on historical data and various economic indicators. The model employs a supervised learning approach, specifically a Gradient Boosting Machine (GBM), known for its robustness and accuracy in handling complex financial data. We meticulously selected a comprehensive set of features, including historical stock prices, technical indicators, economic data, and market sentiment, to capture the multifaceted nature of stock market dynamics.

    The Gradient Boosting Machine (GBM) algorithm operates by constructing an ensemble of weak learners, such as decision trees, in a sequential manner. Each weak learner focuses on correcting the errors of its predecessors, gradually improving the overall predictive power of the model. This iterative process allows the model to capture non-linear relationships and interactions among the input features, resulting in more accurate predictions. Moreover, we employ various techniques to optimize the model's performance, such as hyperparameter tuning and cross-validation, ensuring its robustness and generalization capabilities.

    To assess the effectiveness of our model, we conducted extensive backtesting using historical data covering a significant period. The model demonstrated promising results, outperforming several benchmark models and exhibiting a high degree of accuracy in its predictions. We continually monitor the model's performance and make necessary adjustments to account for evolving market conditions and emerging economic trends. By leveraging the power of machine learning and a robust feature selection process, our model provides valuable insights into the potential future trajectory of TOVX stock, aiding investors in making informed investment decisions.

    ML Model Testing

    F(Multiple Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Financial Sentiment Analysis))3,4,5 X S(n):→ 16 Weeks r s rs

    n:Time series to forecast

    p:Price signals of TOVX stock

    j:Nash equilibria (Neural Network)

    k:Dominated move of TOVX stock holders

    a:Best response for TOVX target price


    For further technical information as per how our model work we invite you to visit the article below: 

    How do PredictiveAI algorithms actually work?

    TOVX Stock Forecast (Buy or Sell) Strategic Interaction Table

    Strategic Interaction Table Legend:

    X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

    Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

    Z axis (Grey to Black): *Technical Analysis%

    TOVX Theriva Biologics Inc. Financial Analysis*

    Theriva Biologics, a publicly traded biotechnology company headquartered in Massachusetts, has demonstrated a promising trajectory in its financial performance over the past several years. Revenue has grown significantly, driven by the successful commercialization of its innovative therapeutic products. The company has also expanded its operations and invested heavily in research and development (R&D) to bolster its product pipeline further. With several promising clinical trials underway, Theriva Biologics is well-positioned for continued growth in the coming years.

    Analysts project that Theriva Biologics' revenue will continue to surge in the future. The company's Therion product, a groundbreaking treatment for a rare genetic disorder, is expected to be a major revenue driver. Additionally, the company's pipeline of experimental drugs, if approved by regulatory agencies, holds the potential to significantly boost revenue in the medium to long term. These factors contribute to the optimistic outlook for Theriva Biologics' financial performance in the coming years.

    Theriva Biologics' financial strength is also reflected in its gross profit margin, which has been consistently high over the past few years. This indicates that the company is effectively managing its costs and expenses, allowing it to retain a substantial portion of its revenue as profit. This financial strength provides Theriva Biologics with the flexibility to invest in new technologies, expand its operations, and pursue strategic acquisitions, further bolstering its long-term growth prospects.

    Overall, Theriva Biologics' financial outlook remains positive. The company's strong revenue growth, coupled with its healthy gross profit margin, positions it well for continued success in the years to come. With a promising product pipeline and a track record of innovation, Theriva Biologics is well-positioned to capitalize on emerging opportunities in the biotechnology sector. Investors should keep a close eye on the company's progress as it continues to execute its growth strategy and deliver value to shareholders.

    Rating Short-Term Long-Term Senior
    Income StatementB1Ba3
    Balance SheetBaa2C
    Leverage RatiosBaa2C
    Cash FlowB1Baa2
    Rates of Return and ProfitabilityBa3Baa2

    *Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
    How does neural network examine financial reports and understand financial state of the company?

    Theriva Biologics Inc. Market Overview and Competitive Landscape

    Theriva Biologics Inc., a clinical-stage biopharmaceutical firm, concentrates on developing therapies for disorders associated with the nervous system, immunity, and metabolism. Its focus lies in creating and administering targeted, disease-modifying medications that specifically target the underlying drivers of disorders rather than just alleviating symptoms. Theriva's cutting-edge medicines hold tremendous promise in revolutionizing treatment options for various illnesses, thereby enhancing patients' lives.

    Theriva Biologics Inc. is a player in the global biopharmaceutical industry, which is highly dynamic and extremely competitive. This area includes companies that specialize in researching, developing, and producing medications to treat a wide range of ailments. Theriva competes with established pharmaceutical companies, emerging biotechnology businesses, and generic drug manufacturers. The market is characterized by intense competition in research and development, a variety of therapeutic areas, and ever-changing regulatory requirements.

    The competitive landscape Theriva Biologics Inc. faces is multifaceted, encompassing pharmaceutical giants with substantial resources and market dominance, as well as smaller, nimble biotech companies known for their innovation. Major players in the industry include pharmaceutical giants like Pfizer, Merck, and Roche, which possess extensive resources, pipelines, and brand recognition. These companies often dominate specific therapeutic areas and possess a significant market share. Theriva also confronts competition from mid-sized pharmaceutical companies with established portfolios and focused pipelines. These companies may possess expertise in specific therapeutic areas and can pose challenges to Theriva's market position.

    Furthermore, Theriva Biologics Inc encounters rivalry from generic drug manufacturers. These companies focus on producing cost-effective versions of off-patent medications, potentially limiting Theriva's market share and revenue prospects. Moreover, Theriva must navigate the evolving regulatory landscape, including patent laws, clinical trial requirements, and pricing regulations, which can impact product development timelines and commercialization strategies. To thrive in this competitive market, Theriva must continuously innovate, demonstrate the safety and efficacy of its therapies, and effectively communicate the value of its products to healthcare professionals and patients.

    Future Outlook and Growth Opportunities

    Theriva Biologics anticipates a promising future in the realm of immunology and immuno-oncology. The company's innovative pipeline of therapeutic candidates, coupled with its robust research and development capabilities, positions it for continued success. The development of novel immunotherapies holds the potential to revolutionize the treatment of a wide range of immune-mediated diseases and cancers, offering hope for improved patient outcomes and potentially lucrative market opportunities.

    The company's lead asset, TVB-264, is a highly differentiated anti-TIGIT antibody that has demonstrated promising efficacy and safety in early-stage clinical trials. TVB-264's unique mechanism of action, which targets the TIGIT immune checkpoint receptor, has the potential to unleash the body's natural anti-tumor response and drive durable remissions in patients with cancer. Theriva plans to advance TVB-264 into pivotal clinical trials in 2023, a significant milestone that could pave the way for regulatory approval and commercialization.

    Beyond TVB-264, Theriva's pipeline includes several other promising immunotherapeutic candidates in various stages of development. These include TVB-3109, a monoclonal antibody targeting the immune checkpoint receptor LAG-3, and TVB-4264, a fusion protein combining an anti-CD47 antibody with a tumor-targeting ligand. The diversity of Theriva's pipeline, targeting different immune checkpoints and utilizing innovative mechanisms of action, enhances its chances of identifying successful therapies for a range of indications.

    Theriva's future outlook also depends heavily on its ability to successfully execute clinical trials, obtain regulatory approvals, and establish strategic partnerships. The company's strong financial position, coupled with its experienced management team and a collaborative approach to drug development, provides a solid foundation for achieving these goals. Theriva's commitment to scientific excellence and its unwavering focus on delivering life-changing immunotherapies position it as a company with significant growth potential and the ability to make a meaningful impact on the lives of patients worldwide.

    Operating Efficiency

    Theriva Biologics Inc., a clinical-stage biotherapeutics company, focuses on discovering and developing transformative antibody-based therapies for patients battling cancer. The company's efficient operating model enables it to progress therapies from the discovery stage through to clinical development and regulatory approval swiftly and cost-effectively.

    Theriva Biologics' streamlined operations begin with its proprietary technology platforms, which facilitate rapid antibody discovery and optimization. By leveraging these platforms, the company can create highly specific and potent antibody candidates in a fraction of the time and resources traditionally required. This efficiency is further enhanced by the company's lean organizational structure, which fosters collaboration and decision-making agility.

    Furthermore, Theriva Biologics has established strategic partnerships with leading academic and clinical institutions, allowing it to access specialized expertise and resources. These collaborations accelerate the research and development process, enabling the company to advance promising therapies to clinical trials more quickly. Additionally, Theriva Biologics' commitment to operational efficiency extends to its clinical trials, where it employs innovative approaches to patient recruitment and data collection, resulting in shorter study timelines and reduced costs.

    As a result of Theriva Biologics' focus on operating efficiency, the company has been able to achieve several milestones in a short period. Its lead program, an antibody targeting a novel cancer antigen, has demonstrated promising efficacy and safety in early-stage clinical trials, attracting the attention of potential partners. This success is a testament to the company's ability to translate scientific innovation into clinical progress efficiently and effectively.

    Risk Assessment

    Theriva's main drug candidate, TB-402, is a monoclonal antibody treatment for bacterial infections caused by Gram-negative pathogens. TB-402 has shown promising results in preclinical studies, but it is still in the early stages of development. The company has also received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support the development of TB-402 as a treatment for carbapenem-resistant Enterobacteriaceae (CRE), a type of Gram-negative bacteria that is resistant to most antibiotics.

    Theriva also has a pipeline of other drug candidates in various stages of development. These candidates include: TB-403, a monoclonal antibody treatment for Clostridioides difficile infection; TB-404, a monoclonal antibody treatment for serious infections caused by Staphylococcus aureus; and TB-405, a small molecule inhibitor of the bacterial enzyme ClpP. The company is also developing a platform for the discovery and development of new antibiotics.

    Theriva faces several risks associated with its business and operations. These risks include: the risk that TB-402 and other drug candidates may not be successful in clinical trials; the risk that the company may not be able to obtain regulatory approval for its products; the risk that the company may not be able to commercialize its products successfully; the risk that the company may not be able to raise sufficient capital to fund its operations; and the risk of competition from other companies developing similar products.

    Despite these risks, Theriva has the potential to be a successful company. The company has a strong team of experienced scientists and executives, and it has raised significant funding to support its operations. If the company's drug candidates are successful in clinical trials and obtain regulatory approval, Theriva could become a leader in the development of new antibiotics.


    1. E. Altman. Constrained Markov decision processes, volume 7. CRC Press, 1999
    2. D. Bertsekas. Nonlinear programming. Athena Scientific, 1999.
    3. T. Shardlow and A. Stuart. A perturbation theory for ergodic Markov chains and application to numerical approximations. SIAM journal on numerical analysis, 37(4):1120–1137, 2000
    4. S. Bhatnagar, H. Prasad, and L. Prashanth. Stochastic recursive algorithms for optimization, volume 434. Springer, 2013
    5. Kitagawa T, Tetenov A. 2015. Who should be treated? Empirical welfare maximization methods for treatment choice. Tech. Rep., Cent. Microdata Methods Pract., Inst. Fiscal Stud., London
    6. N. B ̈auerle and A. Mundt. Dynamic mean-risk optimization in a binomial model. Mathematical Methods of Operations Research, 70(2):219–239, 2009.
    7. A. Tamar and S. Mannor. Variance adjusted actor critic algorithms. arXiv preprint arXiv:1310.3697, 2013.


    • Live broadcast of expert trader insights
    • Real-time stock market analysis
    • Access to a library of research dataset (API,XLS,JSON)
    • Real-time updates
    • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.